Filing Details

Accession Number:
0001104659-22-004515
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-14 18:14:00
Reporting Period:
2022-01-03
Accepted Time:
2022-01-14 18:14:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640266 Voyager Therapeutics Inc. VYGR Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1894915 Julie Burek C/O Voyager Therapeutics, Inc.,
75 Sidney Street
Cambridge MA 02139
Vp, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-31 3,063 $2.30 49,585 No 5 A Direct
Common Stock Disposition 2022-01-03 3,063 $2.83 46,522 No 4 S Direct
Common Stock Disposition 2022-01-12 265 $3.06 46,257 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
  2. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.22, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.